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 2 
Abstract 24 
Multiple sclerosis (MS) is a neuroinflammatory disease with a relapsing-remitting disease course 25 
at early stages, distinct lesion characteristics in cortical gray versus subcortical white matter, and 26 
neurodegeneration at chronic stages. We assessed multilineage cell expression changes using 27 
single-nucleus RNA sequencing (snRNA-seq) and validated results using multiplex in situ 28 
hybridization in MS lesions. We found selective vulnerability and loss of excitatory CUX2-29 
expressing projection neurons in upper cortical layers underlying meningeal inflammation; such 30 
MS neuron populations showed upregulation of stress pathway genes and long non-coding 31 
RNAs. Signatures of stressed oligodendrocytes, reactive astrocytes and activated phagocytosing 32 
cells mapped most strongly to the rim of MS plaques. Interestingly, snRNA-seq identified 33 
phagocytosing microglia and/or macrophages by their ingestion and perinuclear import of myelin 34 
transcripts, confirmed by functional mouse and human culture assays. Our findings indicate 35 
lineage- and region-specific transcriptomic changes associated with selective cortical neuron 36 
damage and glial activation contributing to MS lesion progression.37 
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Multiple sclerosis (MS) is a progressive neuroinflammatory autoimmune disease affecting about 38 
2.3 million people worldwide1.  Immune-mediated cytotoxic damage to oligodendrocytes (OLs) 39 
causes demyelination and focal plaque formation2,3 accompanied by progressive axonal damage 40 
in white matter (WM)4,5, and active MS plaques typically show a rim of inflammation with 41 
myelin phagocytosis. MS lesion heterogeneity in WM versus gray matter (GM) compartments 42 
suggests that the underlying pathobiology and potential for repair is likely to vary in a region-43 
restricted manner.  Cortical GM pathologies include demyelination and damage to the axon, 44 
neurite and neuron cell body6, particularly in areas underlying meningeal inflammation with 45 
plasma cell infiltration7-9. However, whether this process affects all or a subset of cortical 46 
neurons is poorly understood10. Indeed, cell type-specific mechanisms of MS progression, 47 
including scar formation with slowly expanding WM lesions11 and cortical atrophy12 are unclear.  48 
Single-cell transcriptomic techniques are well suited to identify cellular heterogeneity in 49 
the human brain; recently, they have been applied to individual glial lineages in MS13,14. Here, 50 
we took a multilineage approach to brain-resident populations (neurons, astrocytes, OLs, 51 
microglia) to better understand molecular, cellular and spatially-restricted substrates of 52 
progressive MS pathology. We used frozen human brain samples from MS cases and controls to 53 
perform unbiased isolation of nuclei from cortical and subcortical lesion and non-lesion areas 54 
followed by single-nucleus RNA-sequencing (snRNA-seq)13,15 and in situ validation of RNA 55 
gene expression across large anatomical areas. Our results indicate that genes most dysregulated 56 
in MS map spatially to vulnerable upper cortical layer neurons and reactive glia at the borders of 57 
subcortical MS lesions associated with progression in MS58 
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Results 59 
snRNA-seq using post-mortem frozen MS tissue reveals cell-type specific molecular 60 
changes associated with MS pathogenesis. We used snRNA-seq to profile cortical GM and 61 
adjacent subcortical WM MS lesion areas at various stages of inflammation and demyelination, 62 
and control tissue from unaffected individuals. We established a pipeline for serial sectioning of 63 
entire tissue blocks including lesion and non-lesion GM and WM areas plus meningeal tissue. 64 
Tissue sections were screened for RNA integrity number (RIN) of >6.5. Using this criterion, 65 
12/19 MS tissue samples screened from 17 individuals and 9/16 samples screened from control 66 
individuals were further procesed (Fig. 1a; Supplementary Table 1).  Confounding variables of 67 
age, sex, postmortem interval and RIN were not significantly different between control and MS 68 
subjects (p > 0.1, Mann-Whitney U test). 69 
 We optimized and performed unbiased nuclei isolation using sucrose-gradient 70 
ultracentrifugation (Extended Data Fig. 1a), followed by snRNA-barcoding (10x Genomics) 71 
and cDNA sequencing. After quality control filtering, snRNA-seq yielded 48,919 single-nuclei 72 
profiles (Fig. 1b-c). We normalized data and applied several independent analysis techniques. As 73 
shown (Fig. 1c), unbiased clustering identified 22 cell clusters (n.b., none comprised nuclei 74 
captured from individual MS or control samples). We detected a median of 1,400 genes and 75 
2,400 transcripts per nucleus with higher numbers detected in neuronal versus glial populations 76 
(Extended Data Fig. 1b, Supplementary Table 2).  77 
 Next, we annotated cell clusters based on expression of lineage marker genes for 78 
excitatory and inhibitory cortical neurons, astrocytes, OL lineage cells and microglia, as well as 79 
smaller cell populations (Fig. 1d, Extended Data Fig. 1e, Supplementary Table 3)16.  Neuronal 80 
subtype markers included excitatory neuron marker SCL17A7, upper layer marker CUX2, layer 4 81 
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marker RORB, deep layer marker TLE4, as well as interneuron (IN) marker GAD2 and subtype 82 
markers PVALB, SST, VIP and SV2C. Comparing normalized nuclei numbers from MS and 83 
controls (Supplementary Table 4), we observed a selective reduction of upper-layer excitatory 84 
projection neuron (EN-L2-3A/B) numbers in MS samples with cortical demyelination (Fig. 1e-85 
f). In contrast, numbers of intermediate (EN-L4) and deep-layer (EN-L5-6) excitatory neurons, 86 
THY1/NRGN-high-expressing pyramidal cells, VIP-expressing, somatostatin (SST) - and 87 
parvalbumin (PVALB)-expressing INs were similar between MS samples and controls (Fig. 1e-88 
f). MS-associated genes showed greatest differential expression in EN-L2-3, followed by EN-L4 89 
and myelinating OLs (Fig. 1g).  Notably, for EN-L2-3 and OLs, transcriptomic changes 90 
distinguished subclusters from MS or control samples (Fig. 1c and 1e). In contrast to EN-L2-3 91 
cells, gene dysregulation was less pronounced in upper layer VIP-expressing INs (Fig. 1g). 92 
These findings suggested cell-type vulnerability of layer 2/3 excitatory CUX2-expressing 93 
neurons.  94 
 Selective vulnerability of CUX2-expressing upper layer neurons in MS. We 95 
investigated changes in CUX2-expressing EN-L2-3 cells in MS lesion pathology using 96 
unsupervised pseudotime trajectory analysis to identify dynamic gene expression changes. As 97 
shown (Fig. 2a), cell distribution along the trajectory separated control from MS in EN-L2-3 98 
cells. Interestingly, progression along the trajectory correlated with conventional inflammatory 99 
lesion staging and the degree of upper layer cortical demyelination (Fig. 2b, Extended Data Fig. 100 
1c-d), e.g., CUX2-expressing neurons, which localized towards the trajectory end, derived 101 
mainly from samples harboring late chronic inactive lesions with extensive subpial 102 
demyelination versus lesions with less upper cortical demyelination (Fig. 2c). 103 
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Trajectory analysis highlighted gene ontology (GO) terms and dynamic upregulation of 104 
oxidative stress, mitochondrial dysfunction and cell death pathways in EN-L2-3 cells, including 105 
FAIM2, ATF4, CLU, B2M (cell stress/death), HSPH1, HSP90AA1 (heat-shock response), APP, 106 
NEFL, UBB  (protein accumulation, axon degradation), COX7C, PKM, PPIA (energy 107 
metabolism, oxidative stress) and long-noncoding (lnc) RNAs LINC00657 (NORAD) and 108 
BCYRN1 (BC200) (Fig. 2d-e,  Extended Data Fig. 2a, Supplementary Table 5)17,18. 109 
Conversely, we noted dynamic downregulation of transcripts associated with mitochondrial 110 
energy consumption (FARS2), glutamate signaling (GRIA4, GRM5), potassium/cation 111 
homeostasis (KCNB2, KCNN2, SLC22A10), neuronal signaling (NELL1), axon plasticity 112 
(ROBO1) and lncRNA LINC01266 (Fig. 2f). Neurons from all cortical layers in MS showed 113 
enrichment of cell stress pathways compared to controls (Extended Data Fig. 2b, 114 
Supplementary Table 6); in contrast, PVALB- and VIP-expressing INs showed only one GO 115 
term (associated with protein folding) enriched for dysregulated genes. Together, these findings 116 
highlighted a selective transcriptomic damage signature for CUX2-expressing neurons in MS. 117 
Loss of CUX2-expressing neurons in demyelinated cortical MS lesions in situ. We 118 
next used large area spatial transcriptomic (‘LaST’) mapping19 to validate cell type-specific gene 119 
expression changes. We optimized chromogenic and multiplex small molecule fluorescent in situ 120 
hybridization (smFISH) protocols to overcome high levels of background auto-fluorescence in 121 
WM and GM areas in frozen human brain samples. As shown (Fig. 3a), we achieved a favorable 122 
signal-to-noise ratio over tissue sections for neuronal markers CUX2 and SYT1 combined with 123 
immunohistochemistry for myelin oligodendrocyte glycoprotein (MOG), and we confirmed 124 
layer-associated expression of neuronal subtype markers RORB, THY1, TLE4, VIP and SST (Fig. 125 
3a, Extended Data Fig. 3a). 126 
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Given snRNA-seq findings above, we investigated expression of co-located upper layer 127 
CUX2- and VIP-expressing populations by smFISH in MS and control sections (Fig. 3b). We 128 
found a significant reduction of CUX2-expressing neurons in completely and incompletely 129 
demyelinated cortical areas; in contrast, numbers of abutting VIP-expressing INs were 130 
maintained. Of note, meningeal infiltration of IGHG1/ MZB1-expressing plasma cells (that 131 
predominated over SKAP1+ T cells) was a common finding in sulci with underlying upper 132 
cortical layer demyelination and loss of CUX2-expressing neurons (Extended Data Fig. 3b)7,20.  133 
We next used smFISH to validate upregulation of the cell stress markers, including PPIA 134 
(encoding prolyl isomerase cyclophilin A, Extended Data Fig. 2a) in MS EN-L2-3 and EN-L4 135 
neurons. As shown (Fig. 3c), PPIA transcripts were increased in neurons from demyelinated and 136 
adjacent normal-appearing cortical lesion areas21. We confirmed upregulated NORAD in EN-L2-137 
3 and EN-L4 neurons (Extended Data Fig. 2a) by chromogenic and fluorescent smFISH, and 138 
observed cytoplasmic NORAD accumulation in MS lesions as compared to normal-appearing 139 
areas with intact myelin (Fig. 3c). Together, these findings confirm degeneration and selective 140 
loss of CUX2-expressing upper layer excitatory neurons in cortical MS lesions, while co-located 141 
inhibitory and other cortical excitatory neuron subtypes were relatively preserved. 142 
Distinct spatial macroglial signatures in cortical and subcortical MS lesions. Prior 143 
studies have indicated differential gene expression and functionally diverse properties of reactive 144 
astrocytes that can be antagonistic or beneficial to repair after injury22,23. We identified 145 
astrogliosis by enhanced immunoreactivity for glial fibrillary acidic protein (GFAP) in regions of 146 
subcortical demyelinated WM that did not cross into the demyelinated cortex in MS lesions 147 
(Extended Data Fig. 4a). The GFAP signature in demyelinated WM overlapped with CD44-148 
expressing reactive astrocytes24; CD44 showed upregulation at the lesion rim in astrocytes that 149 
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co-expressed CRYAB and MT3 (Extended Data Fig. 4a-b)25.  As shown (Fig. 4a, Extended 150 
Data Fig. 4a), RFX4 expression was specific to the astrocyte lineage and captured all SLC1A2-151 
positive GM and CD44-expressing WM astrocytes (Supplementary Table 3, Extended Data 152 
Fig. 4a). We observed downregulation of genes for glutamate (SLC1A2, GLUL) and potassium 153 
homeostasis (KCNJ10)26 in cortical GM astrocytes and confirmed expression of GPC5, a marker 154 
that co-localizes with RFX4-expressing GM astrocytes, in lesion and non-lesion cortical areas in 155 
situ (Fig. 4a-b, Extended Data Fig. 4a). Reactive astrocytes at inflammatory chronic active 156 
lesion rims showed strong expression of the transcription factors BCL6, FOS (encoding c-FOS) – 157 
associated with astrocyte endothelin receptor type B (EDNRB) upregulation – and LINC01088 158 
(Fig. 4b, Extended Data Fig. 4b)27. Thus, spatial transcriptomics revealed distinct expression 159 
patterns for cortical versus subcortical reactive astrocytes in the MS lesion microenvironment. 160 
Myelinating OLs characterized by myelin gene expression and the transcription factor 161 
ST18 (Fig. 1d, Extended Data Fig. 4c) exhibited the third highest number of differentially 162 
expressed genes (Fig. 1g) consistent with enriched stress pathways (Extended Data Fig. 4d) and 163 
known cell loss in MS. Differential gene expression analysis indicated upregulation of genes for 164 
heat shock response (HSP90AA1) (Extended Data Fig. 4e)34, cell stress (FAIM2, ATF4), MHC 165 
class I upregulation (B2M, HLA-C), iron accumulation (FTL, FTH1)28, ubiquitin-mediated 166 
protein degradation (UBB) and LINC00657 (NORAD) and LINC00844 (Fig. 4c-d, Extended 167 
Data Fig. 2a). Conversely, we observed downregulation of markers for OL differentiation and 168 
myelin synthesis (BCAS1, SGMS1)29, potassium/cation homeostasis (KCNJ10)26, cell-cell-169 
interaction (SEMA6A) and formation of the node of Ranvier (GLDN) in MS OLs at lesion 170 
borders (Fig. 4c). Our findings indicate severe cell stress in MS OLs that can be mapped back to 171 
periplaque rim areas of subcortical lesions. 172 
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Activated phagocytosing microglial cells can be identified by snRNA-seq and 173 
mapped to chronic-active MS lesion rims. Given dramatic expansion of microglia in MS 174 
samples (Fig. 1e), we performed hierarchical clustering (Extended Data Fig. 5) and observed 175 
microglial cells with a homeostatic gene expression signature (P2RY12, RUNX1, CSF1R) in MS 176 
and control samples as well as MS-specific cells with enrichment for transcripts encoding 177 
activation markers, complement factors and MHC-II associated proteins14 , and lipid degradation 178 
(ASAH1, ACSL1, DPYD) (Fig. 5a-b, Extended Data Fig. 5, Supplementary Table S5). 179 
Downregulated genes in MS microglia included synapse remodeling transcript SYNDIG1 and 180 
potassium channel KCNQ3. As shown (Fig. 5a-b), marker genes for microglia reactivity (CD68, 181 
CD74, FTL, MSR1) colocalized with the lineage microglia marker RUNX1, and mapped such 182 
activated cells to chronic active boundaries of subcortical MS lesions.  183 
Interestingly, we found a cluster of microglial cells characterized by phagocytosis and 184 
enrichment for OL-specific markers PLP1, MBP and ST18 (Fig. 1c-d, Extended Data Fig. 4c 185 
and 5, Supplementary Table 7) suggesting the possibility that ingested myelin transcripts co-186 
purified with nuclei of phagocytosing cells in MS. To provide functional evidence for putative 187 
myelin RNA microglial phagocytosis, we cultured human and mouse microglia exposed to 188 
purified myelin from rat brain (Fig. 5c), which contains myelin transcripts (Extended Data Fig. 189 
6)30.  As shown (Fig. 5c), PLP1 and MBP transcripts were observed in intracellular, perinuclear 190 
and nuclear compartments of cultured human or mouse microglia at 1-day post exposure to 191 
labeled (pHrodo) myelin; ingested MBP mRNA was observed in mouse microglia up to 4-days 192 
post-feeding. In parallel, we observed morphological changes in phagocytosing mouse microglia, 193 
differential upregulation of the activation marker Cd163 and downregulation of the homeostatic 194 
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microglia marker P2ry1231. Such changes in mouse microglia showed parallel gene expression 195 
changes in human MS microglia by snRNA-seq (Fig. 5c).   196 
Interactive single-cell web browser to visualize snRNA-seq data. We created an interactive 197 
web browser to analyze cell-type specific expression levels of genes and transcriptomic changes 198 
in MS versus control tissue (https://ms.cells.ucsc.edu).  199 
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Discussion 200 
MS lesions are heterogeneous in cortical and subcortical areas with distinct patterns of 201 
inflammatory demyelination10,32,33. We found cell type-specific gene expression changes in 202 
regions of cortical neurodegeneration and at the rim of chronic active subcortical lesions 203 
involved in progression and cortical atrophy. Our technical finding of snRNA-seq feasibility in 204 
MS is consistent with recent observations13-15. We used high-quality archival samples from 205 
patients, who did not receive modern immunomodulatory therapies; thus, they represent the 206 
endpoint of the natural disease course with relatively early death of patients (30-50 yrs). 207 
However, the number of MS samples studied could have resulted in under-reporting of certain 208 
lineages.  209 
Computational analysis of differential gene expression and trajectory analysis of a total of 210 
12 MS and 9 control samples pointed most strongly to the neuronal compartment and indicated 211 
dramatic cellular stress and loss of CUX2-expressing upper layer excitatory projection neurons in 212 
demyelinated and partially remyelinated cortical MS lesions. As such lesions underlie meningeal 213 
inflammation with pronounced plasma B cell infiltration, these findings suggest the importance 214 
of B cells in progressive MS7,8 and that damaged cortical neuron populations potentially 215 
benefited from B cell depleting therapies34.  216 
We validated candidate gene expression using spatial transcriptomics of human MS 217 
brain.  Markers of stressed CUX2-expressing neurons included PPIA (cyclophilin A) and 218 
NORAD, a neuronal lncRNA that helps stabilize DNA upon genomic stress by binding to 219 
PUMILIO and RBMX proteins 17,35, as well as other pathways for protein degradation, heat 220 
shock response and metabolic exhaustion36,37. Whereas most transcriptional changes and 221 
neuronal cell loss occurred in demyelinated regions, we also observed abnormal gene expression 222 
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features (e.g., PPIA) in normal-appearing cortical areas suggesting a gradient of pathology38. 223 
While it is possible that CUX2-expressing projection neurons are damaged by both sustained 224 
meningeal inflammation and retrograde axon pathology from juxtacortical WM lesions in MS33, 225 
additional intrinsic factors might account for their lack of resilience, especially considering that 226 
neighboring inhibitory and excitatory neurons of the cortex showed relatively little cell loss.    227 
Recent studies used MS WM lesion single-nuclei and single-cell RNA-seq to study the 228 
OL13 and microglia14 lineages and reported subsets linked to MS pathobiology. Here, we used 229 
spatial transcriptomics to map dysregulated glial gene expression in cortical and subcortical 230 
lesion and non-lesion areas. Transcriptomic changes associated with OL, microglia and astrocyte 231 
activation mapped predominantly to the rim areas of chronic active subcortical lesions11,39. In 232 
particular, lesion rim OLs28 showed molecular changes indicating cellular degeneration and iron 233 
overload. Notably, both stressed myelinating OLs and upper layer cortical projection neurons 234 
upregulated genes for self-antigen presentation to immune cells (B2M, HLA-C) suggesting 235 
processes perpetuate degeneration and inflammation40,41. 236 
In another example of spatial diversity in MS, we detected distinct transcripts for cortical 237 
versus subcortical lesion astrocytes, indicating molecular differences in the tissue 238 
microenvironment. Further, we found that snRNA-seq can distinguish phagocytosing cells in MS 239 
based on their transport of ingested myelin transcripts into peri-nuclear structures or the nucleus 240 
itself.  Future work is needed to determine whether this biology is beneficial or detrimental in 241 
disease course, e.g., by exacerbating inflammation. In summary, multilineage and spatial gene 242 
expression analysis indicates cell type-specific neuron vulnerability and glial activation patterns 243 
relevant to neurodegeneration and MS lesion progression. 244 
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Figure legends 281 
Fig. 1. Experimental approach and characteristics of snRNA-seq using frozen MS tissue. 282 
(a) Cortical and subcortical control tissue and MS lesion types (DM = demyelination, NA = 283 
normal appearing). (b) Experimental approach for isolating nuclei from postmortem snap-frozen 284 
brain samples of MS and control patients. (c) Cell types from individual samples (left), cell-type 285 
specific clusters (center; ctrl, n= 9; MS, n= 12) and sample contribution to individual clusters 286 
(right). Note separation of EN-L2-3 and OL cells into MS-specific clusters EN-L2-3-A/B and 287 
OL-B/C. (d) tSNE plots highlight marker genes for neurons, astrocytes, OLs and microglia. (e) 288 
Bar chart shows contributions of normalized control and MS cell numbers to major cell-type 289 
clusters. Note that EN-L2-3-A cell enrichment and concomitant decrease in EN-L2-3-B in 290 
control samples over MS was not statistically significant (p = 0.165 and 0.082). (f) Specific loss 291 
of EN-L2-3 versus EN-L4, EN-L5-6 or IN-VIP neurons based on normalized cell numbers. (g) 292 
Differential gene expression (DGE) analysis showing highest number of dysregulated genes in 293 
EN-L2-3 followed by EN-L4 and OL cells; least differentially expressed genes were found in 294 
SST INs and OPCs. Box plots represent median and interquartile range (IQR) of differentially 295 
expressed gene number calculated after downsampling (100 DGE analyses per cell cluster; ctrl, 296 
n= 9; n= 12 MS). Wiskers extend to the largest values within 1.5 IQR from box boundaries, 297 
outliers shown as dots, notches represent a 95% confidence interval around the median. Two-298 
tailed Mann-Whitney tests performed in e and f (ctrl, n= 9; MS, n= 12); *P ≤ 0.05. Data 299 
presented as mean ± SEM. For tSNE plots, data shown from a total of 48,919 nuclei (ctrl, n= 9; 300 
n= 12 MS). 301 
 302 
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Fig. 2. Pseudotime trajectory analysis of upper layer excitatory projection neurons. (a) 303 
Trajectory analysis of CUX2-expressing EN-L2-3 cells (upper left). Unsupervised pseudotime 304 
trajectories within the EN-L2-3 (upper right) cluster reflected cellular origin from MS samples or 305 
controls (lower left) and inflammatory lesion stage (lower right). (b) EN-L2-3 pseudotime 306 
trajectories showed similar features as (a) and suggested loss of normalized EN-L2-3 numbers 307 
(lower left). Strongest association with EN-L2-3 trajectories found for upper cortical layer 308 
demyelination (upper right) versus deep cortical layer (center right) and subcortical 309 
demyelination (lower right). (c) Note selective enrichment of dysregulated genes in EN-L2-3 310 
cells from samples with late chronic inactive lesions versus acute/chronic-active and control 311 
samples. (d) Visualization of GO terms (enrichment calculated using GSEA, FDR adjusted p ≤ 312 
0.05, no terms significantly decreased) in genes significantly regulated in EN-L2-3 in a 313 
pseudotime-dependent manner (Moran’s I test, FDR adjusted p ≤ 0.0001). Note enrichment of 314 
severe cell stress processes. (e) Trajectory-dependent upregulated (f) and downregulated EN-L2-315 
3 genes of interest. Grey shading represent 95% confidence interval based on gene expression in 316 
all (n= 5,938) sampled EN-L2-3 nuclei. 317 
 318 
Fig. 3. Cellular and molecular neuronal pathology in cortical MS lesions. (a) tSNE plots 319 
CUX2, VIP and TLE4-expressing neurons (left). Spatial transcriptomics showing layer-specific 320 
expression of CUX2 in lesion (indicated by loss of MOG) versus non-lesion areas (center left). 321 
Schematic illustrates layer-specific neuron subtype diversity (center). Note CUX2 and VIP 322 
expression in upper and TLE4 in deep cortical layers by smFISH (center right; ctrl, n=5), and 323 
validation of neuronal expression by SYT1 ISH (black arrowheads; ctrl, n=5). (b) CUX2 and VIP 324 
smFISH demonstrate reduction of CUX2- but not VIP-expressing upper layer neurons in DMGM 325 
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underlying meningeal inflammation (upper left and right) versus incomplete demyelinated 326 
(IDMGM), NAGM and control cortical GM (bottom left). ANOVA with Kruskal Wallis multiple 327 
comparison tests were performed (ctrl, n=5 (CUX2), n=4 (VIP); MS, n=8; *P ≤ 0.05; different 328 
samples with NAWM, IDMGM and DMGM MS lesion areas from same sections; representative 329 
images).  (c) Upregulation of neuronal PPIA in DMGM and NAGM versus control GM (left, 330 
white circles indicate perinuclear areas of PPIA quantification). Neuronal upregulation and 331 
cytoplasmic accumulation of LINC00657 (NORAD) in DMGM versus NAGM and control areas 332 
(right, black arrowheads). ANOVA with Tukey’s multiple comparison tests were performed 333 
(ctrl, n=3; MS, n=4; **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001; different samples with NAWM 334 
and DMGM areas from same sections; representative images). Data presented as mean ± SEM. 335 
For tSNE plots, data shown from a total of 48,919 nuclei (ctrl, n = 9; n = 12 MS). Violin plots 336 
represent DGE (normalized log transformed UMIs) in EN-L2-3 (EN-L2-3-A and EN-L2-3-B) 337 
nuclei (ctrl, n = 3,481; n = 2,639 MS); box plots represent median and standard deviation of 338 
gene expression. 339 
 340 
Fig. 4. Transcriptomic changes in astrocytes and myelinating oligodendrocytes in cortical 341 
and subcortical MS lesions. (a) Downregulation of SLC1A2 and GPC5 and upregulation of 342 
GFAP and CD44 in MS astrocytes (upper left). LaST ISH experiments confirm SLC1A2 343 
downregulation in DMGM underlying meningeal inflammation, whereas CD44 shows 344 
ubiquitous expression in NAWM and PPWM (periplaque white matter, center left) and 345 
upregulation in reactive astrocytes at lesion rims in b1 (center right). Note CD44 and GPC5 co-346 
expression with pan-astrocyte marker RFX4 (white/black arrowheads, lower left and right) and 347 
association of CD44 with fibrous/reactive WM astrocytes and GPC5 with protoplasmic cortical 348 
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GM astrocytes (black arrowheads; right; white star indicates blood vessel). (b) Downregulation 349 
of GLUL and KCNJ10 in MS astrocytes (left). Note differential upregulation of BCL6 and FOS 350 
in reactive astrocytes at PPWM (center, black arrowheads) and LINC01088 in fibrous/reactive 351 
WM astrocytes (right, black arrowhead). (c) Violin plots for selected genes linked to cell stress 352 
(upregulated, top), myelin biosynthesis and axon maintenance (downregulated, bottom) in MS 353 
OLs. (d) FTL and FTH1 upregulation in PLP1-expressing OLs at iron-laden lesions rims (left, 354 
black arrowheads). Note differential upregulation of B2M and HLA-C in PLP1-expressing OLs 355 
at PPWM (right; yellow arrowheads [white arrowheads mark OLs without B2M ISH signals in 356 
NAWM]). For ISH, representative images shown (ctrl, n = 3; n = 4 MS). For tSNE plots, data 357 
shown from a total of 48,919 nuclei (ctrl, n = 9; n = 12 MS). Violin plots represent DGE 358 
(normalized log transformed UMIs) in nuclei (astrocytes: ctrl, n = 1,571; n = 3,810 MS; OLs 359 
[OL-A, OL-B and OL-C]: ctrl, n = 3,070; n = 9,324 MS;); box plots represent median and 360 
standard deviation of gene expression. 361 
 362 
Fig. 5. Transcriptomic changes in activated and phagocytosing microglia subsets. (a) Violin 363 
and tSNE plots for upregulated genes in MS microglia linked to myelin phagocytosis/breakdown 364 
(left), microglia activation and iron handling (center); note downregulation of genes encoding for 365 
synapse function (SYNDIG1) and potassium homeostasis (KCNQ3) (right). (b) Pseudo low 366 
resolution 3D rendering of confocal images showing subcortical WM lesions of different 367 
inflammatory stages by MBP smFISH and CD68 IHC; white arrowheads indicate CD68+ cells 368 
with MBP+ ISH signals; note colocalization of MBP, CD74 and RUNX1 in CD68-positive cells 369 
(center left, white arrowheads). CD68 IHC identifies WM lesion (blood vessel, black star; upper 370 
right) with upregulation of MSR1 at lesion rims, co-expressed with RUNX1 (lower right) and 371 
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FTL (upper right, black arrowheads); representative images from different tissue sections (ctrl, 372 
n=3; MS, n=4). (c) Human (upper left; n=3 individual biopsies) and mouse (upper center right; 373 
n=4 independent cultures) myelin-microglia engulfment assays confirming ingestion of MBP and 374 
PLP1 transcripts derived from rat myelin. Note localization to nuclear/perinuclear spaces (white 375 
arrowheads). Microglia labeled by pHrodo (human) and Iba1/CD68 (mouse) with LMNA/C and 376 
DAPI nuclear counterstain. Schematic illustrates myelin phagocytosis and uptake into microglial 377 
(peri-)nuclear spaces (upper right). MBP persistence up to 4 days after ingestion in mouse 378 
microglia as shown by smFISH (4 independent cultures; lower left); note upregulation of Cd163 379 
and downregulation of P2ry12 in phagocytosing mouse (6 independent cultures) and human MS 380 
microglia (lower right). Two-tailed Mann-Whitney tests performed. Data presented as mean ± 381 
SEM. For tSNE plots, data shown from a total of 48,919 nuclei (ctrl, n = 9; n = 12 MS). Violin 382 
plots represent DGE (normalized log transformed UMIs) in microglia nuclei (ctrl, n = 159; n = 383 
1,524 MS [microglial and phagocytosing cells]); box plots represent median and standard 384 
deviation of gene expression. 385 
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Human tissue samples, ethical compliance and clinical information 493 
All tissue included in this study was provided by the UK Multiple Sclerosis Tissue Bank at 494 
Imperial College, London, UK and the University of Maryland Brain Bank through the NIH 495 
NeuroBioBank. Human MS and control tissues were obtained via a prospective donor scheme 496 
following ethical approval by the National Research Ethics Committee in the UK 497 
(08/MRE09/31). We have complied with all relevant ethical regulations regarding the use of 498 
human postmortem tissue samples. We examined a total of 35 (19 MS and 16 controls) snap-499 
frozen brain tissue blocks obtained at autopsies from 17 MS patients and 16 controls.  500 
RNA extraction and integrity measurements 501 
Frozen brain tissue samples encompassing the entire span of cortical GM with attached meninges 502 
and underlying subcortical WM were sectioned on a CM3050S cryostat (Leica Microsystems) to 503 
collect 100 µm-thick sections for total RNA and nuclei isolation. Total RNA from 10 mg tissue 504 
was isolated using Trizol (Invitrogen) and purified using the RNAeasy Kit (Qiagen) according to 505 
manufacturer’s instructions. Next, we performed RNA integrity analysis on the Agilent 2100 506 
Bioanalyzer using the RNA 6000 Pico Kit (Agilent, 5067-1514). Only samples with an RNA 507 
integrity number (RIN) ≥ 6.5 were used to perform nuclei isolation followed by snRNA-seq as 508 
samples with lower RIN generated low quality data. As the result, we excluded 14 samples (7 509 
MS and 7 control samples) and performed snRNA-seq on total of 12 snap-frozen brain tissue 510 
blocks obtained at autopsies from 7 female and 3 male MS patients (1 primary progressive MS, 9 511 
secondary progressive MS; Supplementary table 1). The age of the MS patients ranged from 34 512 
to 55 years (median 46 years), and the disease duration from 5 to 43 years (median 18 years). For 513 
control tissue, we included a total 9 snap-frozen brain tissue blocks obtained at autopsies from 4 514 
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female and 5 male individuals. The age of control patients ranged from 35 to 82 years (median 515 
54 years; Supplementary table 1). 516 
Nuclei isolation and snRNA-seq on the 10X Genomics platform 517 
Control and MS samples were processed in the same nuclei isolation batch to minimize potential 518 
batch effects. 40 mg of sectioned brain tissue was homogenized in 5 mL of RNAse-free lysis 519 
buffer (0.32M sucrose, 5 mM CaCl2, 3 mM MgAc2, 0.1 mM EDTA, 10 mM Tris-HCl pH 8, 1 520 
mM DTT, 0.1% Triton X-100 in DEPC-treated water) using a glass Dounce homogenizer 521 
(Thomas Scientific) on ice42. The homogenate was loaded into a 30 ml thick polycarbonate 522 
ultracentrifuge tube (Beckman Coulter). 9 ml of sucrose solution (1.8 M sucrose, 3 mM MgAc2, 523 
1 mM DTT, 10 mM Tris-HCl in DEPC-treated water) was added to the bottom of the tube under 524 
the homogenate and centrifuged at 107,000 g for 2.5 hours at 4°C. Supernatant was aspirated, 525 
and nuclei pellet was incubated in 250 µL of DEPC-treated water-based PBS for 20 min on ice 526 
before resuspending the pellet. Nuclei suspension were analyzed for the presence of debris, 527 
nuclei were counted using a hemocytometer and diluted to 2,000 nuclei/µL before performing 528 
single-nuclei capture using the 10X Genomics Single-Cell 3’ system (Extended Data Fig. 1a). 529 
Target capture of 4,000 nuclei per sample was used. Control and MS samples were loaded on the 530 
same 10X chip to minimize potential batch effects. Single-nuclei libraries from individual 531 
samples were pulled and sequenced on the Illumina HiSeq 2500 machine. 10X nuclei capture 532 
and library preparation protocol was carried out according to the manufacturer’s 533 
recommendation without modification. 534 
snRNA-seq data processing with 10X Genomics CellRanger software and data filtering 535 
For library demultiplexing, fastq file generation, read alignment and unique molecular identifier 536 
(UMI) quantification, CellRanger software v 1.3.1 was used. CellRanger was used with default 537 
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parameters, except for using pre-mRNA reference file (ENSEMBL GRCh38) to insure capturing 538 
intronic reads originating from pre-mRNA transcripts abundant in the nuclear fraction.  539 
Individual expression matrices containing numbers of UMIs per gene in each nucleus were 540 
filtered to retain nuclei with at least 500 genes and 1000 transcripts expressed. Genes expressed 541 
in less than three nuclei were filtered out. Mitochondrial RNA genes were filtered out as well to 542 
exclude transcripts originating from outside the nucleus and avoid biases introduced by nuclei 543 
isolation and ultracentrifugation. Individual matrices were combined, UMIs were normalized to 544 
the total UMIs per nucleus and log-transformed.  545 
Dimensionality reduction, clustering and t-SNE visualization 546 
A filtered log-transformed UMI matrix containing genes expressed in more than five cells was 547 
used to perform truncated singular value decomposition (SVD) with k=50. A screen plot was 548 
generated to select the numbers of significant principle components (PCs) by localizing the last 549 
PC before the explained variance reaches plateau. This resulted in selection of 11 PCs. The 550 
significant PCs were used to calculate Jaccard distance-weighted nearest neighbor distances; 551 
number of nearest neighbors was assigned to root square of number of nuclei. The resulting 552 
graph with Jaccard-weighted edges was used to perform Louvain clustering43. To visualize 553 
nuclei transcriptomic profiles in two-dimensional space, t-distributed stochastic neighbor 554 
embedding (t-SNE) was performed44. Several original clusters expressed a combination of cell 555 
type markers, including interneuron subtypes, T cells, B cells, stromal cells and endothelial cells. 556 
These clusters were further subclustered by repeating PCA analysis of selected cell populations 557 
and performing partitioning around medoids (PAM) bi-clustering (Supplementary table 2). 558 
Cell type annotation 559 
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Cell types were annotated based on the expression of known marker genes visualized by t-SNE 560 
plot, as well as by performing unbiased gene marker analysis (Supplementary table 3). For the 561 
latter, MAST was used to perform differential gene expression analysis by comparing nuclei in 562 
each cluster to the rest of nuclei profiles. Genes with a false discovery rate (FDR) <0.05 and at 563 
least two-fold gene expression upregulation were selected as cell type markers. Subtypes of 564 
projection neurons and interneurons were annotated based on combinatorial expression of 565 
inhibitory and excitatory markers and projection neurons and interneuron subtype markers.  566 
Quantification of number of cell for cell types in MS and control samples 567 
To get insight into enrichment or depletion of cell types in MS, numbers of nuclei in each cluster 568 
and individual were normalized to the total number of nuclei captured from each individual. The 569 
following formula was used: 570 
Normalization factor =  571 
 = N(total nuclei in sample)/N(total nuclei in sample with largest number of total nuclei 572 
captured) 573 
Normalized cell number =  574 
= N(raw cell number in a cell types captured from a sample)/Normalization factor 575 
Then, normalized cell numbers in each sample and cell type were compared between MS and 576 
control groups using Mann-Whitney test (Supplementary Table 4). 577 
Differential gene expression analysis based on repeated down sampling 578 
To estimate the degree of disease affection for different CNS cell types, the number of 579 
differentially expressed genes (DEG) between MS patients and controls was used as a surrogate 580 
parameter. We reasoned that the power to identify DEG is partially dependent on the number of 581 
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cells detected in each cluster. Thus, we devised an analytical approach that corrects for cell count 582 
based on repeated down sampling to identical cell numbers for each donor-cluster combination. 583 
Specifically, 100 iterations of down sampling were performed, where 20 cells were randomly 584 
drawn from each donor for each cluster and combined into synthetic bulk samples as input for a 585 
differential gene expression analysis using DESeq2 version 1.20.045. In this case we favored a 586 
computationally less intensive analysis using DESeq2 without covariates on synthetic bulk 587 
samples over MAST to facilitate the execution of a sufficient number of iterations. The results of 588 
this screening approach were plotted as notched box plots and relevant differences between 589 
clusters were assumed where notches did not overlap (Fig. 1g). Notably, very small clusters 590 
which had less than 4 samples with a minimum of 20 cells available, were excluded from the 591 
analysis. 592 
Trajectory pseudotime analysis 593 
A single cell trajectory for excitatory cortical layer 2-3 neurons was determined and analyzed 594 
using the Monocle package version 3 alpha46. FDR-corrected p values were calculated using the 595 
Monocle 3alpha R package using 5,938 EN-L2-3 nuclei (Supplementary Table 5). Briefly, 596 
single cell transcriptomes of all CUX2-expressing cells were dimensionally reduced by principal 597 
component analysis (PCA) followed by uniform manifold approximation and projection 598 
(UMAP). Next, an unsupervised trajectory through the reduced space was identified using the 599 
SimplePPT algorithm. The root of the resulting tree was set to where most cells of the control 600 
samples clustered. Pseudotime values were then automatically assigned to each cell depending 601 
on its distance on the trajectory relative to the root node. Moran’s I test as implemented in 602 
Monocle 3 alpha was used to identify genes significantly regulated over pseudotime. For each 603 
gene the adjusted p value was signed by the direction of regulation determined by comparing 604 
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expression in the first 5% of cells in pseudotime with the last 5%. The resulting gene list, ordered 605 
by signed adjusted p value, was the input for Gene Set Enrichment Analysis (GSEA) to test for 606 
enriched gene ontology (GO) terms using the clusterProfiler package version 3.10.147. Gene sets 607 
with a FDR < 0.05 were considered as significantly enriched. The results of the analysis were 608 
plotted as a GO term map using the emapplot() function of the clusterProfiler package to cluster 609 
terms based on their gene set relation. Clusters of gene sets were annotated with representative 610 
labels. 611 
To analyze enrichment of individual gene sets on a single cell level, we employed the AUCell 612 
algorithm48. The algorithm measures geneset enrichment towards the top of an expression ranked 613 
gene list for each cell. The resulting area under the curve values (AUC) were plotted for all cells 614 
along pseudotime. 615 
Differential gene expression analysis using linear mixed model regression 616 
To identify genes differentially expressed in MS compared to control samples per cell type. P 617 
values were calculated and FDR-corrected using MAST R package. All nuclei from 9 control 618 
and 12 MS samples for corresponding cell types were used (Supplementary Table 6). MAST 619 
was used to perform zero-inflated regression analysis by fitting a linear mixed model. To exclude 620 
gene expression changes stemming from confounders, such as age, sex, RIN, cortical region, 621 
fractions of ribosomal and mitochondrial transcripts, 10X capture batch and sequencing batch, 622 
the following model was fit with MAST: 623 
zlm(~diagnosis + sequencer + (1|ind) + cngeneson + age + sex + RIN + region + Capbatch + 624 
Seqbatch + ribo_perc + mito_perc, sca, method = "glmer", ebayes = F, silent=T) 625 
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Where cngeneson is gene detection rate (factor recommended in MAST tutorial), Capbatch is 626 
10X capture batch, Seqbatch is sequencing batch, ind is individual label, ribo_perc is ribosomal 627 
RNA fraction and mito_perc is mitochondrial RNA fraction. 628 
To identify genes differentially expressed due to the disease effect, likelihood ratio test (LRT) 629 
was performed by comparing the model with and without the diagnosis factor. Genes with at 630 
least 10% increase or decrease in expression in MS vs control and an FDR <0.05 were selected 631 
as differentially expressed. In addition, we calculated raw fold changes of gene expression by 632 
repeating MAST analysis with only the diagnosis factor in the model and filtered out genes with 633 
raw fold change of expression less than 7%. The latter filtering step allowed removing genes, 634 
whose fold change of expression was heavily dependent on the confounding factors, rather than 635 
clinical diagnosis. 636 
Gene Ontology (GO) analysis for differentially expressed genes 637 
PANTHER software (Broad Institute, https://software.broadinstitute.org/panther) was used to 638 
perform statistical overrepresentation tests for DEGs with respect to individual clusters. All 639 
genes expressed in a given cluster were used as a background list, and GO term analysis for 640 
enriched biological processes was performed. Processes with an FDR < 0.05 were considered 641 
and sorted by FDR. 642 
Heatmap data presentation and hierarchical cluster analysis 643 
Hierarchical clustering was performed with the online Morpheus software (Broad Institute, 644 
https://software.broadinstitute.org/morpheus) using 1-Pearson correlation as distance metric and 645 
complete clustering of rows (genes) and columns (cells or samples). To perform hierarchical 646 
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clustering, we used single-nuclei gene expression matrix of cell type markers for lymphocytes, 647 
microglia and phagocytes (Extended Data Fig. 5, Supplementary Table 7).  648 
Immunohistochemistry 649 
16 µm-cryosections were collected on superfrost slides (VWR) using a CM3050S cryostat (Leica 650 
Microsystems) and fixed in either 4% PFA at room temperature (RT) or ice-cold methanol. Next, 651 
sections were blocked in 0.1M PBS/0.1% Triton X-100/ 10% goat/horse/donkey sera for 1 hour 652 
at RT. Primary antibody incubations were carried out overnight at 4°C. The following antibodies 653 
were used for immunohistochemistry: mouse anti-MOG (clone 8-18C5, 1:1,000 [1:200 after in 654 
situ hybridization], Millipore Sigma), rat anti-GFAP (clone 2.2B10, 13-0300, Thermo Fisher, 655 
1:1,000 [1:200 after in situ hybridization]), rat anti-CD3 (clone CD3-12, Bio-Rad, 1:100), rabbit 656 
anti-MZB1 (polyclonal, Thermo Fisher, 1:1,000), rabbit anti-SKAP1 (polyclonal, Sigma Aldrich, 657 
1:100), mouse anti-CD138 (clone DL-101, Biolegend, 1:100), mouse anti-CD68 (clone 514H12, 658 
Bio-Rad, 1:100), mouse anti-Neurofilament H (NF-H), nonphosphorylated (clone SMI32, 659 
801701, Biolegend, 1:10,000), mouse anti-NeuN (clone MAB377, Sigma Aldrich, 1:1,000). 660 
After washing in 0.1M PBS, cryosections were incubated with secondary antibodies diluted in 661 
0.1M PSB/ 0.1% Triton X-100 for 2 hours, RT. For chromogenic assays, sections were incubated 662 
with biotinylated secondary IgG antibodies (1:500, Thermo Fisher) followed by avidin-biotin 663 
complex for 1-hour incubation (1:500, Vector) and subsequent color revelation using 664 
diaminobenzidine according to the manufacturer’s recommendations (DAB, Dako). For 665 
immunofluorescence, Alexa fluochrome-tagged secondary IgG antibodies (1:500, Thermo 666 
Fisher) were used for primary antibody detection. Slides with fluorescent antibodies were 667 
mounted with DAPI Fluoromount-G (SouthernBiotech). Negative control sections without 668 
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primary antibodies were processed in parallel. For diagnostic purposes, hematoxylin and eosin 669 
(HE) and Luxol fast blue (LFB) staining was carried out. 670 
Iron staining 671 
Tissue non-heme iron was stained according to previously published protocols49. Sections of 672 
fixed, frozen human tissue was allowed to warm to room temperature and dried for 15 minutes in 673 
a laminar flow hood. Endogenous peroxidase activity was quenched by immersion in a solution 674 
of 0.3% H2O2 (v/v) in methanol for 20 minutes and washed three times in deionized water 675 
(dH2O). Sections were then placed in a solution of fresh 1% (w/v) potassium ferrocyanide 676 
(Sigma-Aldrich, UK), pH 1 with HCL for 40 minutes, followed by three washes in dH2O. 677 
Sections were then placed in 0.01M NaN3, 0.3% H2O2 in methanol for 60 minutes, followed by 678 
three washes in PBS. Iron staining was intensified using 3’-diaminobenzidine (DAB) (10% v/v) 679 
solution from Pierce DAB substrate kit (Thermo Fisher) in PBS with 0.005% H2O2 (v/v) for five 680 
hours. DAB reaction was halted with three washes in PBS, 1 wash in 100% methanol and a 681 
further three washes in Bond Wash solution (Leica Biosystems).  682 
Chromogenic single/duplex in situ RNA hybridization 683 
Single molecule in situ hybridization was performed according to the manufacturer’s 684 
recommendations (RNAscope 2.5 brown, red and duplex chromogenic manual assay kits, 685 
Biotechne). Sequences of target probes, preamplifier, amplifier, and label probes are proprietary 686 
and commercially available (Advanced Cell Diagnostics). Typically, target probes contain 20 ZZ 687 
probe pairs (approx. 50 bp/pair) covering 1,000 bp. The following human manual RNAscope 688 
assay probes were used: CUX2, RORB, TLE4, THY1, VIP, SST, HSP90AA1, LINC00657, PPIA, 689 
FTL, B2M, PIEZO2, IGHG1, MSR1, LINC01088, GPC5, CD44, BCL6, FOS, EDNRB, ST18, 690 
RUNX1-C2, SLC1A2-C2, CD44-C2, RFX4-C2, PDGFRA-C2, SYT1-C2, PLP1-C2. Following 691 
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red chromogenic single-molecule in situ hybridization, we performed immunohistochemistry 692 
using either chromogenic or fluorescence assays (see above). After duplex single molecule in 693 
situ hybridization we performed hematoxylin staining of nuclei.  694 
Fluorescence multiplex in situ RNA hybridization and human brain tissue optimization 695 
For small molecule fluorescence in situ RNA hybridization (smFISH) on human brain 696 
cryosections performed on an automated BOND RX robotic stainer (Leica), the following 697 
procedure was used.  Fresh snap frozen human brain tissue was cryosectioned and slides 698 
immediately stored at -80°C. Because human brain tissue often showed high levels of 699 
autofluorescence, several treatments were needed to minimize interference with FISH signals. 700 
Using spectral analysis, we identified sources of autofluorescence to be mainly lipofuscin in grey 701 
matter (emission wavelengths ~450-650nm) and collagen/elastin in white matter (emission 702 
wavelengths ~470-520nm). Initial experiments in fixed tissue also displayed low levels of 703 
formaldehyde-induced fluorescence in the green yellow spectra (~420-470nm); thus, sections of 704 
human brain tissue were not formaldehyde-fixed before storage. On the day of the experiment, 705 
with minimal exposure to (RT) air to keep oxidation of endogenous fluorescent proteins low, 706 
slides where directly transferred from -80°C into pre-chilled PFA 4% (methanol-free). Following 707 
45 minutes incubation sections where immediately submerged in boiling citrate buffer (pH 3.0, 708 
Sigma) for 15 minutes to loosen up the recent crosslinking. Slides where then rinsed twice in 709 
PBS and dehydrated. To avoid interference of background fluorescence, experiments were 710 
designed so that low expressing probes were detected using fluorophores with low background, 711 
i.e., Opal 570, Opal 650.  All samples in this study were treated in the same way regardless of 712 
disease/stage and age. The assay was then performed for 2-3 genes by FISH using the 713 
RNAScope LS Multiplex Assay (Biotechne).  714 
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Samples were initially permeabilized with heat and protease treatment to improve probe 715 
penetration and hybridization. For heat treatment, samples were incubated in BOND ER2 buffer 716 
(pH 9.0, Leica) at 95°C for 10 minutes. For protease treatment, samples were incubated in ACD 717 
protease reagent at 42°C for 10 minutes. Prior to probe hybridization, samples were incubated in 718 
hydrogen peroxide for 10 minutes to inactivate endogenous peroxidases and ACD protease. 719 
Subsequently, samples were incubated in target z-probe mixtures (C1-C4) for 2 hours at 42°C. 720 
Each slide wash flushed three times in order to obtain optimal hybridization to transcripts. The 721 
following human RNAScope LS assay probes were used: SYT1, CUX2, LINC00657, B2M, 722 
CD74, RUNX1, RFX4, SLC1A2, CD44, PLP1, MBP.  723 
Following hybridization, branched DNA amplification trees were built through sequential 724 
incubations in AMP1, AMP2 and AMP3 reagents for 15-30 minutes each at 42°C with LS Rinse 725 
buffer (Leica) high stringency washes between incubation steps. After amplification, probe 726 
channels were detected sequentially via HRP-TSA labeling. Here, samples were incubated in 727 
channel-specific HRP reagents for 15 minutes at 42°C, TSA fluorophores for 30 minutes and 728 
HRP blocking reagent for 15 minutes at 42°C. Probes were labeled using Opal 520, 570 and 650 729 
TSA fluorophores (Perkin Elmer, 1:300). Directly following FISH assay, localization of MOG 730 
myelin protein was performed by BOND RX assisted IHC, where samples were incubated with 731 
anti-MOG antibody in blocking solution for 1 hour (1:200). To develop the antibody signal, 732 
samples were incubated in donkey anti-mouse HRP (Abcam, ab205719, 1:500) for 1 hour, TSA-733 
biotin (PE, NEL700A001KT, 1:200) for 10 minutes and streptavidin-conjugated Alexa 700 734 
(Sigma, 1:200) for 30 minutes.  735 
PCR for myelin and neuron transcripts from rat myelin preparations 736 
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RNA from myelin was purified using phenol-chloroform extraction by adding 100 µl of 737 
chloroform (Sigma Aldrich) to 500 µl of Tri-Reagent containing 50 µl of enriched rat CNS 738 
myelin. Samples were vortexed and centrifuged at 12,000 gmax for 15 minutes at 4°C. The upper 739 
aqueous phase was collected and an equal volume of 70% ethanol added and vortexed. RNA was 740 
purified using PureLink RNA Mini-Kit (Thermo Fisher) according to manufactures instructions. 741 
RNA was eluted with 30 µl of RNAse free water and concentration determined using a 742 
SPECTROStar Nano. cDNA was synthesized from 0.3 µg of RNA using SuperScript III 743 
(Thermo Fisher) according to manufactures instructions with or without inclusion of RT enzyme. 744 
PCRs for rat Mbp and synaptophysin (Syp) were performed using 20 µl of PCR MegaMix Blue 745 
(Client Life Science), 1 µl of cDNA and 0.5 µl of 10 µM forward (F) and reverse (R) primers in 746 
an ABI Veriti 96 Well thermal cycler (Thermo-Fisher) for 30 cycles at 950C, 720C and 540C: 747 
Mbp-F: GTGGTATGTGAGCACAGGCT  748 
Mbp-R: TAAAAGCACCTGCTCTGGGG 749 
Syp-F: TGCCATCTTCGCCTTTGCTA 750 
Syp-R: GCCTGTCTCCTTGAACACGA 751 
Amplified products were loaded onto 1% E-Gel (Thermo-Fisher) according to manufactures 752 
instructions and imaged using E-Gel imager (Thermo-Fisher). 753 
Western blot and Coomassie staining for myelin and neuron protein from rat myelin 754 
preparations 755 
15-20 µg of protein were separated on 4-12% Bis-Tris NuPAGE gels (Thermo-Fisher) according 756 
to manufactures instructions. Gels were either stained for total protein using 0.3% w/v brilliant 757 
blue-G (Sigma) in 40% v/v methanol and 7% v/v glacial acetic acid overnight. Destaining was 758 
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done with several washes in 40% v/v methanol and 7% v/v glacial acetic. For Western blotting, 759 
proteins in gels were transferred onto PVDF membranes (Millipore) using Bolt transfer buffer 760 
(Thermo-Fisher) for 1 hour at 15 V constant voltage. Membranes were blocked with Li-Cor 761 
Blocking Buffer (Li-Cor) for 1 hour at room temperature on a platform shaker. Membranes were 762 
incubated overnight in primary antibodies (1:2000 dilution) rabbit-anti-Mbp or mouse-anti-Mog 763 
(Cell Signaling), rabbit-anti Neurofilament heavy or mouse anti-synaptophysin (Sigma) in 50% 764 
Li-Cor Blocking buffer in tris buffered saline with tween-20 (0.001% v/v) (TBS-T). Membranes 765 
were washed three times with TBS-T and Li-Cor 680-RD secondaries (1:5000) (Li-Cor) applied 766 
in 50% v/v Li-Cor Blocking Buffer in TBS-T for 1 hour at room temperature. Membranes were 767 
three times in TBS-T and imaged on a Li-Cor Odyssey (Li-Cor). 768 
Myelin Enrichment assay and polymerase chain reaction 769 
Myelin enrichment of adult rat CNS was performed according to Jahn et al.50. Unless otherwise 770 
stated all buffers were prepared in DEPC treated water and all procedures carried out at 4°C. 771 
Briefly, adult rats were perfused with saline and the brains rapidly dissected, olfactory bulbs 772 
removed and kept on ice. Brains were cut into hemispheres, and one hemisphere was used for 773 
each preparation. Hemispheres were homogenized using a glass Dounce in 6 ml of 0.32 M 774 
sucrose prepared in DEPC treated water with HALT protease inhibitor cocktail without EDTA 775 
(Thermo Fisher). 1ml of homogenate was retained for further biochemical analysis and 6ml of 776 
homogenate loaded on top of 6ml of 0.85 M sucrose treated with DEPC with HALT protease 777 
inhibitors in 14ml thin walled centrifuge tubes (Beckman Coulter, UK). Samples were 778 
centrifuged at 75,000 gmax for 35 minutes at 4°C. The interface between 0.85 and 0.32 M sucrose 779 
was collected, resuspended in water and centrifuged at 75,000 gmax for 15 minutes at 4°C. The 780 
pellet was subjected to two rounds of osmotic shock by resuspension in water, left on ice for 10 781 
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min and centrifuged at 12,500 gmax for 15 minutes at 4°C. The pellet was resuspended in 6 ml of 782 
0.32M sucrose and overlaid on a bed of 0.85 M sucrose and centrifuged at 75,000 gmax for 35 783 
minutes at 4°C. The purified myelin was collected from the 0.32M and 0.85M sucrose interface. 784 
The myelin was then washed in 10 ml of water and centrifuged at 75,000 gmax for 35 minutes at 785 
4°C and resuspended in either 0.25 M bicarbonate pH 8.3 or Tris Buffered Saline (TBS) pH 7.4 786 
to final volume of 400 µl. A 50 µl was retained and 500 µl of Tri-Reagent (Thermo Fisher) was 787 
added to preserve the RNA. Protein concentration was measured using Pierce-BCA Protein 788 
Assay (Thermo Fisher) according to manufactures instructions.  789 
Animals used for myelin-microglia engulfment assays 790 
Wildtype C57Bl/6J mice (stock #000664) were obtained from Jackson Laboratories (Bar Harbor, 791 
ME). All animal experiments were carried out at the animal facility at the University of 792 
Massachusetts Medical School and approved (#A-2496-17) by Animal Care and Use 793 
Committees (IACUC) and performed under NIH guidelines for proper animal welfare. 794 
Purification and treatment of primary mouse microglia 795 
Purified primary brain-derived microglia were obtained from mixed glial cultures by modified 796 
standard protocols as described before51. Briefly, cerebral cortices from male and female 797 
postnatal day 0.5 C57Bl/6J wildtype mice were dissected free of meninges, chopped into small 798 
pieces and mechanically dissociated until a single cell suspension was obtained. Cells were then 799 
seeded in 10 ml DMEM (Thermo Fisher) supplemented with 10% FBS (Life Technologies) and 800 
1% penicillin-streptomycin (Life Technologies) at a density of one brain per 75cm2 flask, and 801 
cultured for 7 days at 37°C in humidified 5% CO2/95% air. By shaking the culture flasks for 3 802 
hours at 180 rpm, loosely adhering microglia were detached. The suspended microglial cells 803 
were seeded onto glass coverslips at a density of 80.000 cells/well in a 24-well plate and cultured 804 
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overnight. 24 h prior to treatment cell culture medium was changed to neurobasal medium 805 
supplemented with 1x sodium pyruvate, 1x B27 (all from Thermo Fisher), 1x GlutaMAX, 1x 806 
penicillin-streptomycin (both from Life Technologies), 5 µg/ml insulin, 1x SATO, 5 µg/ml N-807 
acetyl-L-cysteine, 40 ng/ml T3 (all from Sigma), and 10 ng/ml mouse macrophage colony 808 
stimulating factor (Shenandoah). Finally, microglia were treated with 6.45 µg purified myelin 809 
fraction from rat brain for 4 hours, before myelin was removed and cells were fixed or harvested 810 
for analysis at the indicated time points. To visualize engulfment of myelin proteins into 811 
microglial lysosomes, myelin protein was labeled with pHrodo (Thermo Fisher) under RNase 812 
free conditions according to the manufacture’s recommendations prior to treatment.  813 
Mbp RNA hybridization on primary mouse microglia 814 
RNA in situ hybridization was performed according to the manufacturer’s recommendations 815 
(ACDBio). Briefly, after treatment, cells were fixed with 4% PFA, dehydrated and stored at -816 
20°C for up to 7 days before further use. Prior to RNA hybridization, cells were rehydrated, 817 
rinsed in PBS and treated with 1:15 diluted “Protease III” for 15 minutes at 40°C. Then, probes 818 
against Mbp (ACDBio) were added and incubated for 2 hours at 40°C. Subsequent amplification 819 
steps were performed according to the manufacturer’s instructions. To confirm specificity of 820 
RNA signals, some samples were treated with 10 mg/ml RNaseA (Thermo Fisher Scientific) for 821 
1h at 37°C prior to incubation with probes. To immunostain samples following Mbp RNA 822 
hybridization, cells were washed in PBS, blocked in 2% normal goat serum supplemented with 823 
0.01% TritonX-100 for 30 minutes and incubated with the following primary antibodies: rabbit 824 
polyclonal anti-Iba1 (Wako Chemicals) and rat monoclonal anti-CD68 (clone FA-11, AbD 825 
Serotec, MCA1957) (both 1:100). The following day, cells were incubated with appropriate 826 
Alexa-fluorophore-conjugated secondary antibodies (Thermo Fisher Scientific) and mounted 827 
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with vectashield containing DAPI (Vector laboratories). Random 63x fields of all cultures were 828 
imaged using identical settings on a Zeiss Observer Spinning Disk Confocal microscope 829 
equipped with diode lasers (405nm, 488nm, 594nm, 647nm) and Zen Blue acquisition software 830 
(Zeiss). For unbiased quantification of Mbp puncta, signals were co-localized to Iba1+ microglia 831 
blind to treatment of the samples and the number of total puncta as well as signals associated 832 
with microglia nuclei (0.5µm distance from the nucleus) were determined using ImageJ (NIH). 833 
Moreover, 630x z-stacks were acquired with 35-50 steps at 0.22 µm spacing and processed in 834 
Imaris (Bitplane, Switzerland) to 3D surface render engulfed signals as previously described. 835 
RNA isolation and quantitative reverse transcriptase polymerase chain reaction 836 
Total RNA from microglia was extracted using TRIzol (Life Technologies) acco52rding to 837 
manufacturer’s recommendations. 500 ng total RNA samples were transcribed into cDNA using 838 
Power SYBR™ Green Cells-to-CT Kit (Thermo Fisher Technologies) according to 839 
manufacturer’s instructions. Relative Cd163 and P2ry12 expression was determined by 840 
quantitative polymerase chain reaction (qPCR) in relation to Gapdh housekeeping gene 841 
expression using the following forward (F) and reverse (R) primers: 842 
Cd163-F: GGGTCATTCAGAGGCACACTG 843 
Cd163-R: CTGGCTGTCCTGTCAAGGCT 844 
P2ry12-F: GTTCTACGTGAAGGAGAGCA  845 
P2ry12-R: CTACATTGGGGTCTCTTCGC 846 
Gapdh-F: TGTCCGTCGTGGATCTGAC 847 
Gapdh-R: CCTGCTTCACCACCTTCTTG 848 
Human tissue sampling for primary human microglia assays 849 
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Human brain tissue was obtained with informed consent under protocol REC 16/LO/2168 850 
approved by the NHS Health Research Authority. Adult human brain tissue was obtained from 851 
three biopsies (age 17, male, diffuse axonal injury, right frontal lobe; age 61, male, unruptured 852 
cerebral aneurysm, right gyrus rectus; age 70, male, normal pressure hydrocephalus, right 853 
parietal lobe) taken from the site of neurosurgery resection for the original clinical indication. 854 
Tissue was transferred to Hibernate A low fluorescence (HALF) supplemented with 1x SOS 855 
(Cell Guidance Systems), 2% Glutamax (Life Technologies), 1% P/S (Sigma), 0.1% BSA 856 
(Sigma), insulin (4g/ml, Sigma), pyruvate (220 g/ml, Gibco) and DNase 1 Type IV (40 g/ml, 857 
Sigma) on ice and transported to a dedicated BCL 2 laboratory.  858 
Dissociation of human brain tissue and purification of human microglia 859 
Brain tissue was mechanically digested in fresh ice-cold HALF supplemented with 1x SOS (Cell 860 
Guidance Systems), 2% Glutamax (Life Technologies), 1% P/S (Sigma), 0.1% BSA (Sigma), 861 
insulin (4g/ml, Sigma), pyruvate (220 g/ml, Gibco) and DNase 1 Type IV (40 g/ml, Sigma). The 862 
prepared mix was spun in HBSS+ (Life Technologies) at 300g for 5 mins and supernatant 863 
discarded. The digested tissue was rigorously triturated at 4°C and filtered through a 70µm nylon 864 
cell strainer (Falcon) to remove large cell debris and undigested tissue. Filtrate was spun in a 865 
22% Percoll (Sigma) gradient with DMEM F12 (Sigma) at 800g for 20 minutes. Supernatant was 866 
discarded and the pellet was re-suspended in ice cold supplemented HALF. The isolated cell 867 
suspension was incubated with anti-CD11b conjugated magnetic beads (Miltenyi) for 15 minutes 868 
at 4°C. Cells were washed twice with supplemented HALF and passed through an MS column 869 
(Miltenyi). Each sample was washed three time in the column and then extracted. Cells were 870 
plated in DMEM F12 with 10% foetal bovine serum and 0.1% Macrophage colony-stimulating 871 
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factor (M-CSF). Note that incubators for all cell culture incubators are regularly tested for 872 
mycoplasma contamination. 873 
Mbp and Plp1 RNA hybridization on primary mouse microglia 874 
Purified rat brain myelin extracts from three biological replicates were diluted to 1 mg/mL (total 875 
protein) in 0.1 M sodium bicarbonate buffer, pH 8.3 in a volume of 100 µl. The pH sensitive 876 
fluorescent dye succinimidyl ester known as pHrodoRed (Thermo Fisher) was added from a 10 877 
mM stock in DMSO to a final of 100 µM to each myelin extract for 45 minutes at room 878 
temperature. Samples were centrifuged for 30 minutes at 17,000x g at 4°C and the supernatant 879 
discarded. The labelled myelin pellets were resuspended in 100 µl of 0.1 M sodium bicarbonate 880 
buffer, pH 8.3 to a final of 1mg/ ml of protein and 1.5 µl added to wells of human microglia in 881 
24 well glass bottom plate (Cellvis) for phagocytosis over 18 hours. The next day, the cells were 882 
washed twice with PBS before fixation with 4% PFA at room temperature for 10 minutes and 883 
washing with PBS. 884 
Cells were manually stained for RNA using RNAScope using a modified automated procedure 885 
for the Leica BOND RX (Leica). Fixed cells were washed twice with BOND wash solution 886 
(Leica) before antigen retrieval with BOND Epitope Retrieval Solution 2 (Leica) at 95°C and 887 
allowed to cool to room temperature, and followed by three washes with BOND wash. Cells 888 
were permeabilized with 0.5x RNAScope 2.5 LS Protease III (Biotechne) in PBS at 37°C for 5 889 
min, followed by cold BOND wash (40°C) and then two more BOND washes at room 890 
temperature. Endogenous peroxidase activity was quenched with RNAScope 2.5 LS Hydrogen 891 
Peroxide (Biotechne) for 10 minutes and followed by two more BOND washes. RNAScope 892 
probes for mouse Mbp (Biotechne) and Plp-1 (Biotechne) were diluted 1:50 in C1 probe. Mbp 893 
and Plp-1 probes were amplified using sequential treatments with RNAScope LS Multiplex 894 
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AMP 1, 2 and 3 (Biotechne) for 30 minutes at 42°C with BOND washing and RNAScope 2.5 LS 895 
Rinse Reagent (Biotechne) for 5 minutes each between each amplification step. Probe channel 896 
C2 for Mbp was fluorescently developed using RNAScope Multiplex HRP-C2 (Biotechne) for 897 
15 minutes at 42°C, followed by BOND washes and incubation with tyramide-conjugated Opal 898 
520 dye at 1: 2,500 (Perkin Elmer) for 30 minutes followed with two more BOND washes. 899 
Residual HRP activity was quenched with RNAScope LS Multiplex HRP Blocker (Biotechne) 900 
for 15 minutes at 42°C, followed by BOND washes. Probe channel C3 for Plp-1 was developed 901 
as for C2 but using RNAScope LS Multiplex HRP-C3 (Biotechne) and Opal 650 dye at 1:2,500 902 
(Perkin Elmer, UK) and followed by RNAScope LS Multiplex HRP Blocker (Biotechne) with 903 
BOND washing. Staining of LMNA/C (Laminutes A/C) was done after RNAScope development 904 
by incubating cells with mouse anti-porcine Laminutes A/C antibody (Insight Biotechnology, 905 
UK) at 1:200 and rabbit anti-Iba1 biotin conjugated antibody at 1:200 for 60 minutes at RT. 906 
Excess primary antibodies were washed away with BOND wash and cells incubated goat anti-907 
mouse IgG2B AlexaFlour 350 at 1:500 and streptavidin-conjugated AlexaFlour 700 at 1:1,000 908 
for 60 minutes at RT. Cells were wash three times in BOND wash and twice in PBS before 909 
imaging on an Operetta CLS (Perkin-Elmer) spinning disk confocal microscope. 910 
Image acquisition and analysis of human IHC and ISH experiments 911 
Bright field images were acquired on Zeiss Axio Imager 2 and Leica DMi8 microscopes 912 
equipped with Zeiss Axiocam 512 color and Leica DMC5400 cameras. Fluorescent images were 913 
taken using Leica TCS SP8 and TCS SPE laser confocal and DMi8 widefield (equipped with 914 
Leica DFC7000 GT camera) microscopes with either 10x, 20x, 40x or 63x objectives; all 915 
fluorescent confocal pictures are Z-stack images, unless stated otherwise. High-resolution FISH 916 
images of human tissue sections were acquired on a spinning disk Operetta CLS (Perkin Elmer) 917 
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in confocal mode using a sCMOS camera and a 40X NA 1.1 automated-water dispensing 918 
objective. The field-of-view was 320 x 320 µm and voxel size 0.3 x 0.3 x 1 µm. Each field was 919 
imaged as a z-stack consisting of 20 to 30 planes with a 1 µm step size. z-heights of tissue 920 
sections were manually identified by imaging DAPI on sample fields prior to tissue-wide scans. 921 
Each z-plane was imaged across 5 channels depending on the experiment with exposure between 922 
60 and 120 ms at 90% LED power. 3D projections were generated using raw imaging data in 923 
Volocity 6.3 software (Perkin Elmer). Images were processed using Fiji ImageJ or Photoshop 924 
software (Adobe) and exported to Illustrator vector-based software (Adobe) for figure 925 
generation. 926 
Statistical Analysis 927 
Data are presented as mean ± standard error of mean (SEM). Analyses were performed using 928 
two-tailed parametric or non-parametric (Mann-Whitney, Kruskal-Wallis) t-tests for two groups 929 
and if applicable, one-way ANOVA with corresponding post-hoc tests for multiple group 930 
comparisons. P values were designated as follows: *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, **** p 931 
≤ 0.0001. Analyses were performed using GraphPad Prism (GraphPad Software). 932 
 933 
Data Availability 934 
All raw snRNA-seq data (fastq files) were deposited to the Sequence Read Archive (SRA), 935 
accession number PRJNA544731 (NCBI Bioproject ID: 544731).  936 
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Extended Data Figure legends 967 
Extended Data Fig. 1. Sample and disease contribution of cell types captured by snRNA-968 
seq. (a) Representative images selected from nuclei suspensions (ctrl, n=9; MS, n=12) after 969 
ultracentrifugation and before capturing by 10X Genomics confirming DAPI nuclear 970 
counterstaining with presence of smaller and larger DAPI+ nuclei. Note that larger nuclei are co-971 
stained with anti-NeuN antibody confirming neuronal origin (white arrowheads). (b) Colored t-972 
SNE plots showing numbers of genes (left) and UMIs (right) per captured nuclei from control 973 
and MS samples. (c) Colored t-SNE plot visualizing nuclei from different lesion stages based on 974 
classic pathological MS lesion staging. (d) Colored t-SNE plots visualizing nuclei from samples 975 
with different levels of upper and deep layer cortical demyelination as well as subcortical 976 
demyelination. (e) Representative tSNE plots with cell-type specific marker genes for OL 977 
progenitor cells, stromal cells including pericytes, endothelial cells, and leukocytes. For tSNE 978 
plots, data shown from 9 control and 12 MS samples and a total of 48,919 nuclei. 979 
 980 
Extended Data Fig. 2. Molecular changes in cortical neuron subtypes in MS lesions. (a) 981 
NORAD and PPIA expression patterns in cortical neurons and selected glial subtypes. Note 982 
baseline expression of NORAD and PPIA in neuronal versus glial subtypes and preferential 983 
upregulation of both NORAD and PPIA in upper cortical layer excitatory neurons (EN-L2-3 and 984 
EN-L4) in MS lesion tissue versus deep cortical layer excitatory and inhibitory neurons (EN-L5-985 
6 and IN-SST). For all tSNE and violin plots, data are shown from 9 control and 12 MS samples. 986 
For tSNE plots, data from 48,919 nuclei are shown. For EN-L2-3, EN-L4 and EN-L5-6 violin 987 
plots, data shown from 6,120, 3,125 and 3,058 nuclei. Box plots inside violin plots represent 988 
median and standard deviation of gene expression. (b) Visualization of enriched GO terms in 989 
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EN-L2-3, EN-L4 and EN-L5-6 cells based on differential gene expression analysis (linear mixed 990 
model regression). Binomial test with FDR correction was utilized to calculate FDR-corrected p 991 
values using genes differentially expressed in EN-L2-3, EN-L4 and EN-L5-6 nuclei (n= 428, 992 
364 and 327). 993 
 994 
Extended Data Fig. 3. Cortical neuron and lymphocyte subtype analysis in MS lesions. (a) 995 
tSNE plots for neuron subtype specific expression of RORB, THY1, NRGN, SST, SV2C and 996 
PVALB (left). LaST (ctrl, n= 5) showing layer-specific expression of neuronal RORB in 997 
intermediate cortical layer 4 and widespread expression of pyramidal neuron marker THY1 with 998 
enrichment in layer 5; note that SST-expressing interneurons preferentially map to deep cortical 999 
layers. Co-expression studies (ctrl, n= 5) with SYT1 confirm neuronal expression of RORB, 1000 
THY1 and SST (black arrowheads). (b) Heatmap with hierarchical clustering of lymphocyte-1001 
associated transcripts allowing sub clustering of lymphocytes in T cells, B cells and plasma cells 1002 
based on marker gene expression (upper left). tSNE plots for typical B/plasma cell and T cell 1003 
marker genes enriched in lymphocyte clusters (upper right). IHC for T cell marker SKAP1 1004 
(black arrowheads mark SKAP1+ T cells) together with spatial transcriptomics for B cell-1005 
associated IGHG1 encoding immunoglobulin G1 (IgG1) (magenta-colored arrowheads; lower 1006 
left); note preferential clustering of plasma cell-associated MZB1+ and IGHG1-expressing B 1007 
cells (white arrowheads, lower right) in inflamed meningeal tissue versus mixed T and B cell 1008 
infiltration in perivascular cuffs of subcortical lesions (lower panels). One caveat to these 1009 
findings is the relatively small number of MS cases samples, which limited our ability to cluster 1010 
T cell populations.  For tSNE plots (a, b) and hierarchical clustering (b), data shown from 9 1011 
control and 12 MS samples. For tSNE plots, data shown for all 48,919 nuclei; for hierarchical 1012 
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clustering, data shown from 53 nuclei in the B cell cluster. For ISH and IHC experiments in b, 1013 
representative images shown from individual tissue sections (ctrl, n= 4; MS, n= 7). 1014 
 1015 
Extended Data Fig. 4. Astrocyte and oligodendrocyte cluster analysis and spatial 1016 
transcriptomics in MS lesions. (a) Differential spatial expression patterns of astroglial GFAP in 1017 
subcortical versus cortical demyelination by IHC (left); tSNE plots visualizing astrocyte specific 1018 
genes corresponding to all (RFX4) protoplasmic (SLC1A2, GPC5) and fibrous/reactive astrocytes 1019 
(GFAP, CD44). Quantification of RFX4+ ISH signals per nuclei in GM and WM of control 1020 
samples validates RFX4 as a canonical astrocyte marker (ctrl, n= 5); quantification of GPC5+ 1021 
and CD44+ ISH signals per RFX4+ astrocytes confirms validates GPC5 as protoplasmic GM and 1022 
CD44 as fibrous WM marker. Two-tailed Mann-Whitney tests were performed. Data presented 1023 
as mean ± SEM.  (b) Upregulation of astroglial CRYAB, MT3 (black arrowheads) and endothelin 1024 
type B receptor transcript EDNRB (white arrowhead) in reactive astrocytes in subcortical lesions. 1025 
(c) tSNE plots showing OL-specific expression of myelin genes MBP, CNP and transcription 1026 
factor ST18; note co-expression of ST18 with PLP in control WM by ISH. (d) Visualization of 1027 
enriched GO terms in myelinating OLs based on differential gene expression analysis. Binomial 1028 
test with FDR correction was utilized to calculate FDR-corrected p values using 151 genes 1029 
differentially expressed in OLs. (e) Co-expression spatial transcriptomic studies confirming 1030 
upregulation of heat shock protein 90 transcript HSP90AA1 in both progenitor (PDGFRA-1031 
expressing) and myelinating (PLP1-expressing) OLs at lesion rims (PPWM, black arrowheads). 1032 
For tSNE and violin plots, data shown from 9 control and 12 MS samples. For astrocyte violin 1033 
plots, 1,571 control and 3,810 MS nuclei are shown. Box plots inside violin plots represent 1034 
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median and standard deviation of gene expression. For ISH and IHC experiments, representative 1035 
images from  from 3 control and 4 MS individual tissue sections are shown. 1036 
 1037 
Extended Data Fig. 5. Cluster analysis of activated and phagocytosing microglia subtypes. 1038 
Hierarchical cluster analysis identifies several homeostatic and activated MS-specific microglia 1039 
subtypes according to inflammatory lesion stages allowing transcriptomic staging of microglia 1040 
subtypes. Clusters with enriched genes are marked and annotated a-f (see Supplementary Table 1041 
8 for gene list). Note that phagocytosing cells are identified by presence of OL/myelin genes 1042 
(cluster “f” on bottom of heatmap). 1043 
 1044 
Extended Data Fig. 6. PCR for rat Mbp from myelin preparation. (a) Representative 1045 
Coomassie stain of brain homogenate (Hom.) and purified myelin (P.M.) from adult rat brain 1046 
(left). Western blots for myelin basic protein (Mbp), myelin oligodendrocyte glycoprotein 1047 
(Mog), synaptophysin (Syp) and neurofilament heavy molecular weight (NF-H) (center). PCRs 1048 
of myelin basic protein (Mbp) and synaptophysin (Syp) transcripts in brain homogenate and 1049 
purified myelin fractions (right). (b) Densitometric quantification of myelin and homogenates 1050 
prepared from n= 4 independent rat hemispheres for Coomassie (total protein), Western blot 1051 
proteins and PCRs shown in (a) of purified myelin fractions normalized to their respective 1052 
homogenates. Data is shown as median and error bars ± standard error of the mean of the 4 1053 
biological replicates. Similar results were obtained with Hom. and P.M. fractions not used in this 1054 
study. P values calculated from Students’s two tailed t-test with Welch's correction and p values 1055 
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